Damien Dombrowski has experience in all aspects of patent litigation, bench/jury trials, and Federal Circuit appeals, on behalf of plaintiffs and defendants. His experience includes patented technologies related to pharmaceuticals and formulation technology for the treatment of cancer, systemic fungal infections, psoriasis, and respiratory conditions; cancer immunotherapy vaccines; eye vitamin supplements for macular degeneration; DNA sequencing technology; and hardware and software for image sensors and touchscreens/displays. He also has significant experience with due diligence, complex multiparty settlement and license agreements, license/contract disputes, and opinion work.
LEO Pharmaceutical Products, Ltd. v. Rea
Federal Circuit (2013)
Damien was on the team that secured a decision in favor of LEO Pharma, reversing the determination of the Board of Patent Appeals and Interferences that LEO Pharma's U.S. Patent No. 6,753,013 for Taclonex® was obvious.